BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32864713)

  • 41. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
    Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
    Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular and immunological mechanisms of clonal evolution in multiple myeloma.
    Forster S; Radpour R; Ochsenbein AF
    Front Immunol; 2023; 14():1243997. PubMed ID: 37744361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.
    Jirabanditsakul C; Dakeng S; Kunacheewa C; U-Pratya Y; Owattanapanich W
    Technol Cancer Res Treat; 2022; 21():15330338221111228. PubMed ID: 35770320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma.
    Atalay F; Ateşoğlu EB; Yıldız S; Firatlı-Tuglular T; Karakuş S; Bayık M
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):164-70. PubMed ID: 25445472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.
    Szabo AG; Gang AO; Pedersen MØ; Poulsen TS; Klausen TW; Nørgaard P
    Leuk Lymphoma; 2016 Nov; 57(11):2526-34. PubMed ID: 27243588
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Descriptive analysis of genetic aberrations and cell of origin in Richter transformation.
    Chitalia A; Swoboda DM; McCutcheon JN; Ozdemirli M; Khan N; Cheson BD
    Leuk Lymphoma; 2019 Apr; 60(4):971-979. PubMed ID: 30632835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
    Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
    Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
    Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
    Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple myeloma: Every year a new standard?
    Rajkumar SV
    Hematol Oncol; 2019 Jun; 37 Suppl 1(Suppl 1):62-65. PubMed ID: 31187526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
    Lan Y; Zhao E; Luo S; Xiao Y; Li X; Cheng S
    Breast Cancer Res Treat; 2019 May; 175(1):91-104. PubMed ID: 30739230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience.
    Duek A; Trakhtenbrot L; Avigdor A; Nagler A; Leiba M
    Acta Haematol; 2021; 144(1):58-65. PubMed ID: 32512574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
    Liu P; Leong T; Quam L; Billadeau D; Kay NE; Greipp P; Kyle RA; Oken MM; Van Ness B
    Blood; 1996 Oct; 88(7):2699-706. PubMed ID: 8839865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.
    Kridel R; Chan FC; Mottok A; Boyle M; Farinha P; Tan K; Meissner B; Bashashati A; McPherson A; Roth A; Shumansky K; Yap D; Ben-Neriah S; Rosner J; Smith MA; Nielsen C; Giné E; Telenius A; Ennishi D; Mungall A; Moore R; Morin RD; Johnson NA; Sehn LH; Tousseyn T; Dogan A; Connors JM; Scott DW; Steidl C; Marra MA; Gascoyne RD; Shah SP
    PLoS Med; 2016 Dec; 13(12):e1002197. PubMed ID: 27959929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
    Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
    Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in the pathogenesis and diagnosis of multiple myeloma.
    Chesi M; Bergsagel PL
    Int J Lab Hematol; 2015 May; 37 Suppl 1():108-14. PubMed ID: 25976968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple myeloma.
    Röllig C; Knop S; Bornhäuser M
    Lancet; 2015 May; 385(9983):2197-208. PubMed ID: 25540889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.
    Barrio S; Shanafelt TD; Ojha J; Chaffee KG; Secreto C; Kortüm KM; Pathangey S; Van-Dyke DL; Slager SL; Fonseca R; Kay NE; Braggio E
    Leukemia; 2017 Jan; 31(1):170-176. PubMed ID: 27469216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.